ALX Oncology Holdings(ALXO)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

ALXO ALX Oncology Holdings

交易中 10-02 09:32:22 EDT

1.35

+0.05

+3.46%

最高1.35	最低1.30	成交量4,989
今开1.32	昨收1.30	日振幅3.46%
总市值1.86亿	流通市值1.27亿	总股本1.38亿
成交额6,511	换手率0.01%	流通股本9,474万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"ALXO","market":"US","secType":"STK","nameCN":"ALX Oncology Holdings","latestPrice":1.345,"timestamp":1790947937876,"preClose":1.3,"halted":0,"volume":4989,"delay":0,"changeRate":0.03461538461538456,"floatShares":94742400,"shares":138276997,"eps":-1.15,"marketStatus":"交易中","change":0.045,"latestTime":"10-02 09:32:22 EDT","open":1.32,"high":1.345,"low":1.3,"amount":6511.308537000001,"amplitude":0.034615,"askPrice":1.38,"askSize":1364,"bidPrice":1.3,"bidSize":337,"shortable":3,"etf":0,"ttmEps":-1.15,"tradingStatus":2,"nextMarketStatus":{"tag":"盘后交易","tradingStatus":3,"beginTime":1790971200000},"marketStatusCode":2,"adr":0,"listingDate":1594958400000,"exchange":"NASDAQ","adjPreClose":1.3,"preHourTrading":{"tag":"盘前","latestPrice":1.3,"preClose":1.3,"latestTime":"07:49 EDT","volume":263,"amount":347.16,"timestamp":1790941744282,"change":0,"changeRate":0,"amplitude":0.020231},"postHourTrading":{"tag":"盘后","latestPrice":1.35,"preClose":1.3,"latestTime":"19:45 EDT","volume":12629,"amount":16494.11,"timestamp":1790898315156,"change":0.05,"changeRate":0.038462,"amplitude":0.038462},"volumeRatio":0.41959,"impliedVol":0.6962,"impliedVolPercentile":0.259},"requestUrl":"/m/hq/s/ALXO","defaultTab":"news","newsList":[{"id":"1112033269","title":"ALX Oncology任命斯科特·加兰为董事会主席，迈克尔·利斯特加滕为总法律顾问","url":"https://stock-news.laohu8.com/highlight/detail?id=1112033269","media":"美股速递","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1112033269?lang=zh_cn&edition=full","pubTime":"2026-06-30 20:03","pubTimestamp":1782821033,"startTime":"0","endTime":"0","summary":"ALX Oncology Holdings（ALXO）宣布，任命斯科特·加兰为董事会主席，并任命迈克尔·利斯特加滕为总法律顾问。\n加兰先生在生物技术行业拥有深厚的领导经验，其加入有望为董事会带来战略视野。同时，利斯特加滕先生将负责公司的法律事务与合规管理，强化企业治理结构。\n此次高层人事变动，标志着公司正加强其治理团队，以支持未来的业务发展。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ALXO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1173249915","title":"ALX Oncology Holdings与汇丰创投达成贷款及担保协议","url":"https://stock-news.laohu8.com/highlight/detail?id=1173249915","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1173249915?lang=zh_cn&edition=full","pubTime":"2026-06-27 04:04","pubTimestamp":1782504251,"startTime":"0","endTime":"0","summary":"ALX Oncology Holdings于2026年6月25日与汇丰创投签署了一份贷款及担保协议。该协议的相关细节已通过美国证券交易委员会（SEC）的文件予以披露。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALXO","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1131482559","title":"ALX Oncology联合疗法在晚期HER2阳性乳腺癌高CD47表达患者中展现持久疗效","url":"https://stock-news.laohu8.com/highlight/detail?id=1131482559","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1131482559?lang=zh_cn&edition=full","pubTime":"2026-05-07 20:04","pubTimestamp":1778155488,"startTime":"0","endTime":"0","summary":"ALX Oncology旗下药物Evorpacept与Zanidatamab的联合治疗方案，在治疗晚期HER2阳性且CD47高表达乳腺癌患者的临床研究中取得突破性进展。最新数据显示，该疗法不仅能诱发显著的治疗反应，更展现出令人鼓舞的持久疗效。值得注意的是，在CD47高表达的患者亚群中，联合疗法呈现出尤为突出的应答持续性和疾病控制效果。研究人员指出，该组合疗法为传统HER2靶向治疗耐药的患者提供了新的治疗方向。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ALXO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2518274387","title":"Alx Oncology Holdings Inc.盘中异动 早盘急速跳水5.60%","url":"https://stock-news.laohu8.com/highlight/detail?id=2518274387","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2518274387?lang=zh_cn&edition=full","pubTime":"2025-03-10 22:59","pubTimestamp":1741618792,"startTime":"0","endTime":"0","summary":"北京时间2025年03月10日22时59分，Alx Oncology Holdings Inc.股票出现波动，股价急速下挫5.60%。截至发稿，该股报1.00美元/股，成交量42.57万股，换手率0.80%，振幅6.60%。Alx Oncology Holdings Inc.股票所在的生物技术行业中，整体涨幅为0.40%。Alx Oncology Holdings Inc.公司简介：ALX Oncology Holdings Inc是一家临床阶段的免疫肿瘤公司，专注于帮助患者对抗癌症，开发一个基于蛋白质工程和肿瘤专业知识的候选产品管道，以CD47阻断剂evorpacept为首，目前处于1期和2期临床试验。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250310225952abf31d3d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250310225952abf31d3d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ALXO","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2518849482","title":"Alx Oncology Holdings Inc.2024财年实现净利润-1.35亿美元，同比增加16.15%","url":"https://stock-news.laohu8.com/highlight/detail?id=2518849482","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2518849482?lang=zh_cn&edition=full","pubTime":"2025-03-10 00:01","pubTimestamp":1741536075,"startTime":"0","endTime":"0","summary":"3月10日，Alx Oncology Holdings Inc.公布财报，公告显示公司2024财年净利润为-1.35亿美元，同比增加16.15%；其中营业收入为0.00美元，每股基本收益为-2.58美元。从资产负债表来看，Alx Oncology Holdings Inc.总负债34.16百万美元，其中短期债务2.35百万美元，资产负债比为0.05，流动比率为0.08。机构评级：截至2025年3月10日，当前有5家机构对Alx Oncology Holdings Inc.目标价做出预测，其中目标均价为4.14美元，其中最低目标价为1.50美元，最高目标价为9.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250310000233abf1756a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250310000233abf1756a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ALXO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2517453312","title":"Stifel：维持ALX Oncology Holdings(ALXO.US)评级，由持有调整至持有评级, 目标价由3.00美元调整至1.50美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2517453312","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2517453312?lang=zh_cn&edition=full","pubTime":"2025-03-08 00:52","pubTimestamp":1741366373,"startTime":"0","endTime":"0","summary":"Stifel：维持ALX Oncology Holdings(ALXO.US)评级，由持有调整至持有评级, 目标价由3.00美元调整至1.50美元。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/03/08005248604793.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["ALXO","ALX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1152886927","title":"ALX Oncology Holdings 2024财年第四季度调整后每股收益$(0.44)，好于预期的$(0.67)","url":"https://stock-news.laohu8.com/highlight/detail?id=1152886927","media":"财报速递","labels":["express"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1152886927?lang=zh_cn&edition=full","pubTime":"2025-03-07 05:19","pubTimestamp":1741295978,"startTime":"0","endTime":"0","summary":"ALX Oncology Holdings 报告称季度每股亏损$，好于分析师一致预期的$，高出34.33%。这比去年同期每股亏损$增加了44.3%。以上内容来自Benzinga Earnings专栏，原文如下：$ALX Oncology Holdings$  reported quarterly losses of $ per share which beat the analyst consensus estimate of $ by 34.33 percent. This is a 44.3 percent increase over losses of $ per share from the same period last year.","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALX","ALXO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2517655561","title":"Alx Oncology Holdings Inc.盘中异动 早盘大幅拉升5.29%报1.10美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2517655561","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2517655561?lang=zh_cn&edition=full","pubTime":"2025-03-06 22:31","pubTimestamp":1741271470,"startTime":"0","endTime":"0","summary":"北京时间2025年03月06日22时31分，Alx Oncology Holdings Inc.股票出现异动，股价急速拉升5.29%。截至发稿，该股报1.10美元/股，成交量36.2202万股，换手率0.69%，振幅1.92%。Alx Oncology Holdings Inc.股票所在的生物技术行业中，整体跌幅为0.63%。Alx Oncology Holdings Inc.公司简介：ALX Oncology Holdings Inc是一家临床阶段的免疫肿瘤公司，专注于帮助患者对抗癌症，开发一个基于蛋白质工程和肿瘤专业知识的候选产品管道，以CD47阻断剂evorpacept为首，目前处于1期和2期临床试验。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306223110989eb3d4&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306223110989eb3d4&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","ALXO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2517926071","title":"Alx Oncology Holdings Inc.盘中异动 临近收盘股价大涨5.00%","url":"https://stock-news.laohu8.com/highlight/detail?id=2517926071","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2517926071?lang=zh_cn&edition=full","pubTime":"2025-03-06 04:37","pubTimestamp":1741207053,"startTime":"0","endTime":"0","summary":"北京时间2025年03月06日04时37分，Alx Oncology Holdings Inc.股票出现波动，股价急速拉升5.00%。截至发稿，该股报1.05美元/股，成交量50.3409万股，换手率0.95%，振幅6.23%。Alx Oncology Holdings Inc.股票所在的生物技术行业中，整体涨幅为1.93%。Alx Oncology Holdings Inc.公司简介：ALX Oncology Holdings Inc是一家临床阶段的免疫肿瘤公司，专注于帮助患者对抗癌症，开发一个基于蛋白质工程和肿瘤专业知识的候选产品管道，以CD47阻断剂evorpacept为首，目前处于1期和2期临床试验。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306043733989d947e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306043733989d947e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ALXO","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2516563996","title":"Alx Oncology Holdings Inc.盘中异动 大幅跳水5.00%报1.05美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2516563996","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2516563996?lang=zh_cn&edition=full","pubTime":"2025-03-04 00:47","pubTimestamp":1741020444,"startTime":"0","endTime":"0","summary":"北京时间2025年03月04日00时47分，Alx Oncology Holdings Inc.股票出现异动，股价快速下跌5.00%。Alx Oncology Holdings Inc.股票所在的生物技术行业中，整体跌幅为0.40%。Alx Oncology Holdings Inc.公司简介：ALX Oncology Holdings Inc是一家临床阶段的免疫肿瘤公司，专注于帮助患者对抗癌症，开发一个基于蛋白质工程和肿瘤专业知识的候选产品管道，以CD47阻断剂evorpacept为首，目前处于1期和2期临床试验。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250304004725abe65d79&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250304004725abe65d79&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ALXO","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2514138125","title":"Alx Oncology Holdings Inc.盘中异动 快速拉升5.66%报1.12美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2514138125","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2514138125?lang=zh_cn&edition=full","pubTime":"2025-02-27 23:37","pubTimestamp":1740670670,"startTime":"0","endTime":"0","summary":"北京时间2025年02月27日23时37分，Alx Oncology Holdings Inc.股票出现异动，股价急速拉升5.66%。截至发稿，该股报1.12美元/股，成交量11.1284万股，换手率0.21%，振幅7.72%。Alx Oncology Holdings Inc.股票所在的生物技术行业中，整体涨幅为0.70%。Alx Oncology Holdings Inc.公司简介：ALX Oncology Holdings Inc是一家临床阶段的免疫肿瘤公司，专注于帮助患者对抗癌症，开发一个基于蛋白质工程和肿瘤专业知识的候选产品管道，以CD47阻断剂evorpacept为首，目前处于1期和2期临床试验。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202502272337519632bff8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202502272337519632bff8&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","ALXO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2513224697","title":"Alx Oncology Holdings Inc.盘中异动 大幅跳水5.36%报1.06美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2513224697","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2513224697?lang=zh_cn&edition=full","pubTime":"2025-02-24 22:31","pubTimestamp":1740407506,"startTime":"0","endTime":"0","summary":"北京时间2025年02月24日22时31分，Alx Oncology Holdings Inc.股票出现异动，股价大幅下挫5.36%。截至发稿，该股报1.06美元/股，成交量5744股，换手率0.01%，振幅2.68%。Alx Oncology Holdings Inc.股票所在的生物技术行业中，整体跌幅为0.12%。Alx Oncology Holdings Inc.公司简介：ALX Oncology Holdings Inc是一家临床阶段的免疫肿瘤公司，专注于帮助患者对抗癌症，开发一个基于蛋白质工程和肿瘤专业知识的候选产品管道，以CD47阻断剂evorpacept为首，目前处于1期和2期临床试验。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250224223146abdb0dcd&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250224223146abdb0dcd&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","ALXO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2512165330","title":"Alx Oncology Holdings Inc.盘中异动 早盘股价大涨5.00%报1.16美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2512165330","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2512165330?lang=zh_cn&edition=full","pubTime":"2025-02-18 22:33","pubTimestamp":1739889223,"startTime":"0","endTime":"0","summary":"北京时间2025年02月18日22时33分，Alx Oncology Holdings Inc.股票出现异动，股价大幅拉升5.00%。截至发稿，该股报1.16美元/股，成交量1.9453万股，换手率0.04%，振幅3.18%。Alx Oncology Holdings Inc.股票所在的生物技术行业中，整体跌幅为0.08%。Alx Oncology Holdings Inc.公司简介：ALX Oncology Holdings Inc是一家临床阶段的免疫肿瘤公司，专注于帮助患者对抗癌症，开发一个基于蛋白质工程和肿瘤专业知识的候选产品管道，以CD47阻断剂evorpacept为首，目前处于1期和2期临床试验。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025021822334396279799&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025021822334396279799&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","ALXO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2510387270","title":"Alx Oncology Holdings Inc.盘中异动 快速下跌5.76%","url":"https://stock-news.laohu8.com/highlight/detail?id=2510387270","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2510387270?lang=zh_cn&edition=full","pubTime":"2025-02-11 22:34","pubTimestamp":1739284474,"startTime":"0","endTime":"0","summary":"北京时间2025年02月11日22时34分，Alx Oncology Holdings Inc.股票出现波动，股价快速下跌5.76%。Alx Oncology Holdings Inc.股票所在的生物技术行业中，整体跌幅为0.96%。Alx Oncology Holdings Inc.公司简介：ALX Oncology Holdings Inc是一家临床阶段的免疫肿瘤公司，专注于帮助患者对抗癌症，开发一个基于蛋白质工程和肿瘤专业知识的候选产品管道，以CD47阻断剂evorpacept为首，目前处于1期和2期临床试验。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250211223434a241fbb1&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250211223434a241fbb1&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ALXO","OCEA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2510892747","title":"Alx Oncology Holdings Inc.盘中异动 临近收盘快速下跌5.05%","url":"https://stock-news.laohu8.com/highlight/detail?id=2510892747","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2510892747?lang=zh_cn&edition=full","pubTime":"2025-02-11 04:39","pubTimestamp":1739219955,"startTime":"0","endTime":"0","summary":"北京时间2025年02月11日04时39分，Alx Oncology Holdings Inc.股票出现波动，股价大幅跳水5.05%。Alx Oncology Holdings Inc.股票所在的生物技术行业中，整体跌幅为0.98%。Alx Oncology Holdings Inc.公司简介：ALX Oncology Holdings Inc是一家临床阶段的免疫肿瘤公司，专注于帮助患者对抗癌症，开发一个基于蛋白质工程和肿瘤专业知识的候选产品管道，以CD47阻断剂evorpacept为首，目前处于1期和2期临床试验。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202502110439169880bd68&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202502110439169880bd68&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","ALXO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2509742726","title":"Alx Oncology Holdings Inc.盘中异动 早盘急速跳水5.00%报1.14美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2509742726","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2509742726?lang=zh_cn&edition=full","pubTime":"2025-02-07 22:44","pubTimestamp":1738939442,"startTime":"0","endTime":"0","summary":"北京时间2025年02月07日22时44分，Alx Oncology Holdings Inc.股票出现异动，股价大幅跳水5.00%。截至发稿，该股报1.14美元/股，成交量6.7337万股，换手率0.13%，振幅3.92%。Alx Oncology Holdings Inc.股票所在的生物技术行业中，整体涨幅为0.17%。Alx Oncology Holdings Inc.公司简介：ALX Oncology Holdings Inc是一家临床阶段的免疫肿瘤公司，专注于帮助患者对抗癌症，开发一个基于蛋白质工程和肿瘤专业知识的候选产品管道，以CD47阻断剂evorpacept为首，目前处于1期和2期临床试验。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250207224402987daff6&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250207224402987daff6&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","ALXO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2509232542","title":"Alx Oncology Holdings Inc.盘中异动 股价大跌5.43%","url":"https://stock-news.laohu8.com/highlight/detail?id=2509232542","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2509232542?lang=zh_cn&edition=full","pubTime":"2025-02-06 01:31","pubTimestamp":1738776711,"startTime":"0","endTime":"0","summary":"北京时间2025年02月06日01时31分，Alx Oncology Holdings Inc.股票出现异动，股价大幅下挫5.43%。Alx Oncology Holdings Inc.股票所在的生物技术行业中，整体涨幅为2.00%。Alx Oncology Holdings Inc.公司简介：ALX Oncology Holdings Inc是一家临床阶段的免疫肿瘤公司，专注于帮助患者对抗癌症，开发一个基于蛋白质工程和肿瘤专业知识的候选产品管道，以CD47阻断剂evorpacept为首，目前处于1期和2期临床试验。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250206013151abc3a428&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250206013151abc3a428&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["KTTA","ALXO","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2508463243","title":"Alx Oncology Holdings Inc.盘中异动 大幅下跌5.26%报1.25美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2508463243","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2508463243?lang=zh_cn&edition=full","pubTime":"2025-02-04 23:38","pubTimestamp":1738683483,"startTime":"0","endTime":"0","summary":"北京时间2025年02月04日23时38分，Alx Oncology Holdings Inc.股票出现异动，股价急速下挫5.26%。截至发稿，该股报1.25美元/股，成交量8.9478万股，换手率0.17%，振幅3.74%。Alx Oncology Holdings Inc.股票所在的生物技术行业中，整体涨幅为0.77%。Alx Oncology Holdings Inc.公司简介：ALX Oncology Holdings Inc是一家临床阶段的免疫肿瘤公司，专注于帮助患者对抗癌症，开发一个基于蛋白质工程和肿瘤专业知识的候选产品管道，以CD47阻断剂evorpacept为首，目前处于1期和2期临床试验。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250204233803a23935ff&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250204233803a23935ff&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ALXO","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2508149333","title":"Alx Oncology Holdings Inc.盘中异动 早盘股价大跌6.82%报1.36美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2508149333","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2508149333?lang=zh_cn&edition=full","pubTime":"2025-02-03 22:32","pubTimestamp":1738593155,"startTime":"0","endTime":"0","summary":"北京时间2025年02月03日22时32分，Alx Oncology Holdings Inc.股票出现波动，股价急速下跌6.82%。截至发稿，该股报1.36美元/股，成交量9884股，换手率0.02%，振幅0.00%。Alx Oncology Holdings Inc.股票所在的生物技术行业中，整体跌幅为0.51%。Alx Oncology Holdings Inc.公司简介：ALX Oncology Holdings Inc是一家临床阶段的免疫肿瘤公司，专注于帮助患者对抗癌症，开发一个基于蛋白质工程和肿瘤专业知识的候选产品管道，以CD47阻断剂evorpacept为首，目前处于1期和2期临床试验。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202502032232359616fb94&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202502032232359616fb94&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ALXO","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.alxoncology.com","stockEarnings":[{"period":"1week","weight":-0.0406},{"period":"1month","weight":-0.3434},{"period":"3month","weight":-0.372},{"period":"6month","weight":-0.3401},{"period":"1year","weight":-0.2818},{"period":"ytd","weight":0.1504}],"compareEarnings":[{"period":"1week","weight":-0.0042},{"period":"1month","weight":0.0029},{"period":"3month","weight":0.0258},{"period":"6month","weight":0.1649},{"period":"1year","weight":0.1429},{"period":"ytd","weight":0.1204}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"ALX Oncology Holdings Inc.于2020年4月1日成立。该公司是一家临床阶段的免疫肿瘤学公司，专注于通过开发阻断CD47免疫检查点和连接先天和适应性免疫系统的疗法来帮助患者对抗癌症。","yearOnYearQuotes":[{"month":1,"riseRate":0.166667,"avgChangeRate":-0.021509},{"month":2,"riseRate":0.666667,"avgChangeRate":-0.026406},{"month":3,"riseRate":0,"avgChangeRate":-0.198245},{"month":4,"riseRate":0.333333,"avgChangeRate":0.026871},{"month":5,"riseRate":0.333333,"avgChangeRate":-0.12217},{"month":6,"riseRate":0.5,"avgChangeRate":-0.056802},{"month":7,"riseRate":0.5,"avgChangeRate":0.03024},{"month":8,"riseRate":0.571429,"avgChangeRate":0.144585},{"month":9,"riseRate":0.428571,"avgChangeRate":-0.011416},{"month":10,"riseRate":0.428571,"avgChangeRate":0.019525},{"month":11,"riseRate":0.5,"avgChangeRate":0.074796},{"month":12,"riseRate":0.666667,"avgChangeRate":0.109411}],"exchange":"NASDAQ","name":"ALX Oncology Holdings","nameEN":"ALX Oncology Holdings"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"ALX Oncology Holdings(ALXO)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供ALX Oncology Holdings(ALXO)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"ALX Oncology Holdings,ALXO,ALX Oncology Holdings股票,ALX Oncology Holdings股票老虎,ALX Oncology Holdings股票老虎国际,ALX Oncology Holdings行情,ALX Oncology Holdings股票行情,ALX Oncology Holdings股价,ALX Oncology Holdings股市,ALX Oncology Holdings股票价格,ALX Oncology Holdings股票交易,ALX Oncology Holdings股票购买,ALX Oncology Holdings股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"ALX Oncology Holdings(ALXO)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供ALX Oncology Holdings(ALXO)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}